KRAS and neoplasm: Loss of the tumor suppressor PTEN hyperactivates phosphoinositide-3-kinase (PI3K)–AKT signaling and metabolic processes such as glucose metabolism, de novo lipid synthesis, and redox balance [126] and cooperates with mutant KRAS-driven events in multiple PDAC models [127–130].